151 related articles for article (PubMed ID: 38644278)
21. Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study.
Ma J; Yao S; Li XS; Kang HR; Yao FF; Du N
Medicine (Baltimore); 2015 Oct; 94(42):e1489. PubMed ID: 26496252
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.
Wang F; Qu A; Sun Y; Zhang J; Wei B; Cui Y; Liu X; Tian W; Li Y
Br J Radiol; 2021 Aug; 94(1124):20201088. PubMed ID: 34260297
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway.
Cheng R; Li B; Wang H; Zeng Y
Clin Transl Oncol; 2023 Nov; 25(11):3122-3138. PubMed ID: 37036597
[TBL] [Abstract][Full Text] [Related]
25. [Utilization of multimodal therapy concepts in stomach carcinoma in Germany].
Bösing NM; Heise JW; Röher HD
Zentralbl Chir; 2000; 125(4):341-7. PubMed ID: 10829314
[TBL] [Abstract][Full Text] [Related]
26. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
Lee JM; Tsuboi M; Brunelli A
Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
[TBL] [Abstract][Full Text] [Related]
27. A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study.
Zhou M; Yang W; Xuan Y; Zou W; Wang Y; Zhang Z; Zhang J; Mo M; Zhou C; Liu Y; Zhang W; Zhang Z; He Y; Weng W; Tan C; Wang L; Huang D; Sheng W; Li H; Zhu H; Wang Y; Shen L; Zhang H; Wan J; Li G; Huang H; Wang Y; Zhang Z; Liu X; Xia F
BMC Cancer; 2022 Jun; 22(1):710. PubMed ID: 35764956
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study.
Xu C; Xie X; Kang N; Jiang H
J Cancer Res Clin Oncol; 2023 Jul; 149(7):4091-4099. PubMed ID: 36042044
[TBL] [Abstract][Full Text] [Related]
29. [Chinese expert consensus on perioperative treatment of locally advanced gastric cancer (2021 version)].
Gastric Cancer Association, China Anti-Cancer Association
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):741-748. PubMed ID: 34530553
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China.
Yang Y; Tan L; Hu J; Li Y; Mao Y; Tian Z; Zhang B; Ma J; Li H; Chen C; Chen K; Han Y; Chen L; Liu J; Yu B; Yu Z; Li Z;
Dis Esophagus; 2022 Nov; 35(11):. PubMed ID: 35649396
[TBL] [Abstract][Full Text] [Related]
31. [Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors
in Non-small Cell Lung Cancer].
Shu C; Zhu D; Zhou Q
Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):130-136. PubMed ID: 35224967
[TBL] [Abstract][Full Text] [Related]
32. Postoperative chemoradiotherapy in patients with locally advanced gastric cancer with poor pathologic response to neoadjuvant chemotherapy.
Gal O; Lewin R; Perl G; Ulitzky O; Brenner B; Kundel Y
J Cancer Res Ther; 2024 Jan; 20(1):281-284. PubMed ID: 38554334
[TBL] [Abstract][Full Text] [Related]
33. [Historical evolution and research progress of perioperative therapy of locally advanced gastric cancer].
Chen J; Ye Q; Huang F
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):196-200. PubMed ID: 30799543
[TBL] [Abstract][Full Text] [Related]
34. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study.
Ding P; Guo H; Sun C; Yang P; Kim NH; Tian Y; Liu Y; Liu P; Li Y; Zhao Q
BMC Gastroenterol; 2022 Mar; 22(1):121. PubMed ID: 35287591
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort.
Jiang Q; Liu W; Zeng X; Zhang C; Du Y; Zeng L; Yin Y; Fan J; Yang M; Tao K; Zhang P
Front Immunol; 2023; 14():1122121. PubMed ID: 37215127
[TBL] [Abstract][Full Text] [Related]
36. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant and adjuvant approaches in gastroesophageal cancers.
Scheck MK; Masetti M; Lorenzen S
Curr Opin Oncol; 2023 Jul; 35(4):318-325. PubMed ID: 37222198
[TBL] [Abstract][Full Text] [Related]
38. Current status of immunotherapy for advanced gastric cancer.
Kawazoe A; Shitara K; Boku N; Yoshikawa T; Terashima M
Jpn J Clin Oncol; 2021 Jan; 51(1):20-27. PubMed ID: 33241322
[TBL] [Abstract][Full Text] [Related]
39. Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy?
Bozkaya Y; Özdemir NY; Sezer S; Köstek O; Demirci NS; Yazıcı O; Erdem GU; Eren T; Zengin N
Cancer Biomark; 2018; 22(1):143-149. PubMed ID: 29562501
[TBL] [Abstract][Full Text] [Related]
40. Current treatment and recent progress in gastric cancer.
Joshi SS; Badgwell BD
CA Cancer J Clin; 2021 May; 71(3):264-279. PubMed ID: 33592120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
